175 results
Page 5 of 9
8-K
EX-99.1
ljfnk7w ednu
23 Jul 20
Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500
7:05am
8-K
EX-99.2
c6uq26n
23 Jul 20
Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500
7:05am
8-K
wkw04 slab8c
23 Jul 20
Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500
7:05am
424B3
ziqnm 75tiapvme7w
14 Jul 20
Prospectus supplement
4:05pm
8-K
EX-10.3
cj5bh8ahgk5x98
9 Apr 20
Aravive Announces Board Composition and Executive Management Transitions
4:43pm
8-K
EX-99.1
vnp7a
27 Mar 20
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020
8:05am
8-K
EX-99.2
3zrtk5uqj
27 Mar 20
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020
8:05am
8-K
wfo3pi5tzrc6n
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
EX-99.2
mnjhffs5qjxen8qq
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
EX-99.1
eg3eapy88u3xlcraoc
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
EX-99.1
vb33qepixej i3
13 Jan 20
Other Events
8:06am
8-K
EX-10.1
qrzvh pkgmvmx
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-10.3
s4oac7 yv0kx8bje30ix
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-99.1
l63rnq34sm7tu9
20 Dec 19
Regulation FD Disclosure
8:10am